Report ID: 10085606 |
Published Date: 21 Mar 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Global Duloxetine API Market Highlights Over 2022 - 2031
The global duloxetine API market is estimated to grow at a ~4% CAGR over the forecast period, i.e., 2022 – 2031. Moreover, the market registered a notable revenue in 2021. The growth of the market can be attributed to the rise in the number of people dealing with depression, which can lead to suicide. As per the World Health Organization, more than 700,000 people every year die due to suicide. Moreover, duloxetine API molecules are used for the formulation of medicines that provides relief to patients suffering from neuropathic pain. In addition, growing clinical trials is anticipated to surge the growth of the global duloxetine API market.
GET A SAMPLE COPY OF THIS REPORT
The global duloxetine API market is segmented by application into neuropathic pain, generalized anxiety disorder, major depressive disorder, chronic musculoskeletal pain, and others. Out of which, the major depressive disorder segment is anticipated to have the highest share with the fastest CAGR over the forecast period owing to the rise in the number of patients dealing with depression and an increase in the number of suicides across the globe.
Global Duloxetine API Market Regional Synopsis
Regionally, the global duloxetine API market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in the Asia Pacific region is estimated to witness modest growth over the forecast period on the back of an increase in suicidal cases and a rise in spending on the healthcare sector. Moreover, the Asia region accounts for 60 percent of suicide cases worldwide every year. In addition, there has been a surge in API manufacturers that are expected to increase the growth of the duloxetine API market in the region.
Market Segmentation
Our in-depth analysis of the global duloxetine API market includes the following segments:
By End-Users
-
Hospital
-
Pharmaceutical & Bioapplication Industries
-
Others
By Application
-
Neuropathic Pain
-
Generalized Anxiety Disorder
-
Major Depressive Disorder
-
Chronic Musculoskeletal Pain
-
Others
Growth Drivers and Challenges Impacting the Growth of the Global Duloxetine API Market
Growth Drivers
-
Rise in the number of people dealing with depression
-
Growing clinical trials on the API molecules
Challenges
-
High cost for the manufacturing of medicine
-
Lack of inventory
Key Companies Dominating the Global Duloxetine API Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global duloxetine API market that are included in our report are Teva Pharmaceutical Industries Ltd., Lupin Limited, Hetero Healthcare Limited, Apotex Inc., SHIONOGI & Co., Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, GPT Pharma, Zhejiang Huahai Pharmaceutical Co., Ltd, Zydus Group, and others.
Latest Developments in the Global Duloxetine API Market:
-
17 May 2022: Apotex Inc., announced the launch of APO-Teriflunomide tablets, a generic version of Aubagio, in Canada for the treatment of relapsing-remitting multiple sclerosis (RRMS).
-
27 April 2022: Lupin Limited (Lupin) announced a strategic partnership with Yabao Pharmaceutical Co., Inc. (Yabao) to meet the growing demand for quality drugs with pediatric formulations in Chinese markets.
Key Reasons to Buy Our Report
-
The report covers a detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis, and challenges that impact market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
Frequently Asked Question
The market is segmented by end-users, application, and by region.
The major depressive disorder segment is anticipated to hold largest market size in value over the forecast period and display significant growth opportunities.
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10085606 |
Published Date: 21 Mar 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
